|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0022671,
umls-concept:C0038317,
umls-concept:C0072980,
umls-concept:C0080103,
umls-concept:C0085149,
umls-concept:C0086045,
umls-concept:C0178602,
umls-concept:C0376622,
umls-concept:C0444506,
umls-concept:C1413882,
umls-concept:C1514873,
umls-concept:C1704939,
umls-concept:C1823242,
umls-concept:C1882417
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-10-26
|
|
pubmed:abstractText |
CYP3A5 and MDR1 polymorphisms have been shown to influence tacrolimus blood concentrations and dose requirements. The aim is to determine whether these polymorphisms also affect sirolimus trough concentrations and dose requirements after kidney transplantation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/CYP3A5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP3A,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/Steroids,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
pubmed-author:De MeyerMartineM,
pubmed-author:EddourDjamila ChaibDC,
pubmed-author:GarrigueValérieV,
pubmed-author:HaufroidVincentV,
pubmed-author:LisonDominiqueD,
pubmed-author:MalaiseJacquesJ,
pubmed-author:MouradGeorgesG,
pubmed-author:MouradMichelM,
pubmed-author:SquiffletJean PaulJP,
pubmed-author:Van BellingenChristopheC,
pubmed-author:Van KerckhoveValérieV,
pubmed-author:WallemacqPierreP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
977-84
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16249748-Adult,
pubmed-meshheading:16249748-Cytochrome P-450 CYP3A,
pubmed-meshheading:16249748-Cytochrome P-450 Enzyme System,
pubmed-meshheading:16249748-Dose-Response Relationship, Drug,
pubmed-meshheading:16249748-Female,
pubmed-meshheading:16249748-Genotype,
pubmed-meshheading:16249748-Humans,
pubmed-meshheading:16249748-Immunosuppressive Agents,
pubmed-meshheading:16249748-Kidney Transplantation,
pubmed-meshheading:16249748-Male,
pubmed-meshheading:16249748-Middle Aged,
pubmed-meshheading:16249748-P-Glycoprotein,
pubmed-meshheading:16249748-Polymorphism, Genetic,
pubmed-meshheading:16249748-Prednisone,
pubmed-meshheading:16249748-Sirolimus,
pubmed-meshheading:16249748-Steroids,
pubmed-meshheading:16249748-Tacrolimus
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
|
|
pubmed:affiliation |
Kidney and Pancreas Transplantation Unit, Université Catholique de Louvain, Saint Luc University Hospital, Brussels, Belgium. Michel.Mourad@chir.ucl.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|
